AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29979445
Drug: Dexmedetomidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.5 μg/kg over 10 minutes before anesthesia induction and then 0.5 μg/kg/h until peritoneal closure)
Trial: 26803950
Drug: Botulinum toxin-A
RxNorm normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Botulinum toxin-A injections (BoNT-A) in the parotid glands only
Trial: 25078309
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg simeprevir and 400 mg sofosbuvir daily for 24 weeks with ribavirin (group 1)
Trial: 25078309
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg simeprevir and 400 mg sofosbuvir daily for 24 weeks without ribavirin (group 2)
Trial: 25078309
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg simeprevir and 400 mg sofosbuvir daily for 12 weeks with ribavirin (group 3)
Trial: 25078309
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg simeprevir and 400 mg sofosbuvir daily for 12 weeks without ribavirin (group 4)
Trial: 22446502
Drug: Imatinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib treatment with BCR-ABL transcript levels >10% at 3 months
Trial: 22446502
Drug: Imatinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib treatment with BCR-ABL transcript levels >1-10% at 3 months
Trial: 22446502
Drug: Imatinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib treatment with BCR-ABL transcript levels ≤1% at 3 months
Trial: 22446502
Drug: Imatinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib treatment with >35% Philadelphia chromosome-positive metaphases at 3 months
Trial: 22446502
Drug: Imatinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib treatment with ≤35% Philadelphia chromosome-positive metaphases at 3 months
Trial: 22446502
Drug: Imatinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib treatment with BCR-ABL transcript levels >1% at 6 months
Trial: 22446502
Drug: Imatinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib treatment with BCR-ABL transcript levels ≤1% at 6 months
Trial: 22446502
Drug: Imatinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib treatment with >0% Philadelphia chromosome-positive at 6 months
Trial: 22446502
Drug: Imatinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib treatment with 0% Philadelphia chromosome-positive at 6 months
Trial: 11764109
Drug: Group G:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group G: Saliva contamination
Trial: 1284157
Drug: Placebo (i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (i.v. 10-ml bolus)
Trial: 1818002
Drug: Atenolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (5 mg over 5 min)
Trial: 2857523
Drug: Beta-blockade therapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockade therapy (BB) with metoprolol, titrated from 12.5 to 50 mg twice daily, final average dose 61 mg/day
Trial: 2857523
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (C) alone
Trial: 2857523
Drug: Beta-blockade therapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockade therapy (BB)
Trial: 31427046
Drug: Quarterly fremanezumab
RxNorm normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Quarterly fremanezumab (675 mg month 1; placebo months 2 and 3)
Trial: 31427046
Drug: Monthly fremanezumab
RxNorm normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Monthly fremanezumab (225 mg in episodic migraine and 675 mg in chronic migraine month 1; 225 mg months 2 and 3)
Trial: 17908184
Drug: Lotion treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotion treatment
Trial: 14732734
Drug: Repeated oral
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated oral melatonin (2.5 mg) intake 1 hour before sleep for 3 weeks
Trial: 14732734
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of melatonin (2.5 mg)
Trial: 7852749
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg per day
Trial: 7852749
Drug: Lisinopril 10
RxNorm normalized name: lisinopril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 10 mg per day
Trial: 7852749
Drug: Nifedipine 20
RxNorm normalized name: nifedipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 20 mg retard twice a day
Trial: 7852749
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 weeks prior to treatment)
Trial: 2789428
Drug: Exogenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous recombinant human EGF (hEGF) infusion (0.25-1.0 micrograms/kg)
Trial: 2789428
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of pentagastrin
Trial: 31530611
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (4.4 g/day DHA orally)
Trial: 31530611
Drug: Placebo (equal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (equal fat supplement of vegetable oil)
Trial: 26466913
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy plus psychotherapy (pyridoxine hydrochloride 40 mg daily for 3 weeks + mindfulness-based cognitive therapy in eight 50 min sessions over 3 weeks)
Trial: 26466913
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy alone (pyridoxine hydrochloride 40 mg daily for 3 weeks)
Trial: 15687411
Drug: Macronutrient content
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Macronutrient content (e.g., low-fat vs. low-carbohydrate diets)
Trial: 11278151
Drug: Other antipsychotic
RxNorm normalized name: Other antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antipsychotic drugs (comparison group)
Trial: 10028794
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral dosage of 6 mg/kg of elemental iron (Group A)
Trial: 10028794
Drug: Intermittent oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent oral dosage of 6 mg/kg of elemental iron, 3 days a week (Group B)
Trial: 7986970
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg t.d.s. with meals plus amoxycillin 750 mg t.d.s. with meals for 10 days
Trial: 7986970
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg each evening for 6 weeks (for ulcer healing)
Trial: 7986970
Drug: Clarithromycin and
RxNorm normalized name: lansoprazole, clarithromycin and tinidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin and amoxycillin therapy
Trial: 113217
Drug: Atenolol (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (selective beta-1 blocker)
Trial: 30623736
Drug: Intracanal cryotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracanal cryotherapy (20 mL sterile cold saline solution at 2.5 °C for 5 min)
Trial: 30623736
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (sterile saline solution at room temperature)
Trial: 27323324
Drug: Radial extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial extracorporeal shock wave therapy (rESWT) plus physical therapy
Trial: 27323324
Drug: Sham shock
RxNorm normalized name: house dust allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham shock wave plus physical therapy
Trial: 23421363
Drug: Texas Implementation
RxNorm normalized name: influenza A virus A/Texas/50/2012 (H3N2) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Texas Implementation of Medication Algorithm (TIMA) for Bipolar Disorder
Trial: 22117977
Drug: Subcutaneous transposition
RxNorm normalized name: CONNECTOR,ENFIT TRANSITIONAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous transposition
Trial: 15299099
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (HSC infusion)
Trial: 9096446
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) continued for another 12 months
Trial: 3698519
Drug: Local beta-receptor
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local beta-receptor blockade
Trial: 4576562
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cyclophosphamide and nandrolone decanoate
Trial: 27129426
Drug: High-dose trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose trivalent inactivated influenza vaccine (HD TIV)
Trial: 27129426
Drug: Standard-dose trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose trivalent inactivated influenza vaccine (SD TIV)
Trial: 25188774
Drug: Clonidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (150 μg) as an adjuvant to levobupivacaine (Chirocaine)
Trial: 22024920
Drug: Budesonide/formoterol 160 μg/4.5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol 160 μg/4.5 μg ten inhalations daily for 3 days via Turbuhaler®
Trial: 22024920
Drug: Terbutaline 0.4 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline 0.4 mg ten inhalations daily for 3 days via Turbuhaler®
Trial: 361059
Drug: diflucortolone valerate
RxNorm normalized name: diflucortolone valerate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diflucortolone valerate 0.3% ointment
Trial: 361059
Drug: clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: clobetasol propionate 0.05% ointment
Trial: 23830094
Drug: UMEC/VI 62.5/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UMEC/VI 62.5/25 mcg
Trial: 20829308
Drug: Fluoxetine medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine medication
Trial: 19480657
Drug: Buspirone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (30 mg p.o.)
Trial: 19480657
Drug: Morphine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (10 mg i.v.)
Trial: 11224753
Drug: MultiHance (gadobenate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MultiHance (gadobenate dimeglumine) cumulative doses
Trial: 8284093
Drug: Dexamethasone treatment
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone treatment at day 10 (n = 14)
Trial: 8284093
Drug: Dexamethasone treatment
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone treatment at day 16 (n = 13)
Trial: 29283590
Drug: Pacing, Graded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pacing, Graded Activity, and Cognitive Behavioral Therapy
Trial: 25453534
Drug: Nesiritide therapy
RxNorm normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nesiritide therapy
Trial: 18586762
Drug: Intravenous C.E.R.A.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous C.E.R.A. administered once every 2 weeks (Q2W)
Trial: 18586762
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa (DA) administered once weekly (QW)
Trial: 17139037
Drug: Group cognitive-behavioural
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive-behavioural therapy
Trial: 12919163
Drug: Hydrocortisone 10
RxNorm normalized name: hydrocortisone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 10 mg with breakfast and 5 mg with lunch (Schedule 1)
Trial: 12919163
Drug: Hydrocortisone with
RxNorm normalized name: Hydrocortisone with Aloe
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone with the addition of 5 mg with the evening meal (Schedule 2)
Trial: 12919163
Drug: Dexamethasone 0.1
RxNorm normalized name: dexamethasone 0.15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.1 mg/15 kg body weight given per day with breakfast only (Schedule 3)
Trial: 12919163
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three treatment schedules
Trial: 8909439
Drug: Peptide T
RxNorm normalized name: Peptide T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide T 6 mg/day
Trial: 1857947
Drug: Glycine solution
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glycine solution
Trial: 1857947
Drug: Glucose (WHO)
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucose (WHO) solution
Trial: 1857947
Drug: Polycose solution
RxNorm normalized name: POLYCOSE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polycose solution
Trial: 1857947
Drug: Rice-flour solution
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice-flour solution
Trial: 6354523
Drug: Percutaneous dihydrotestosterone
RxNorm normalized name: 2α-Methyl-4,5-dihydrotestosterone propionate
DrugBank: Drostanolone propionate (DB14655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Percutaneous dihydrotestosterone (DHT) 125 mg twice daily
Trial: 6354523
Drug: DHT therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHT therapy (group B)
Trial: 6354523
Drug: DHT treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHT treatment (group A)
Trial: 30873752
Drug: Safety and
RxNorm normalized name: HYDROCORTISONE ACETATE 10 mg in 1 g TOPICAL CREAM [American Safety and First Aid]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and injury prevention contact control (CC)
Trial: 29149143
Drug: TAP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP block with 20 mL per side of 0.25% bupivacaine plus 2 mL magnesium sulphate 10% (200 mg)
Trial: 29149143
Drug: TAP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP block with 20 mL per side of 0.25% bupivacaine
Trial: 16706948
Drug: Safe Sea
RxNorm normalized name: ZINC OXIDE 10.9 g in 100 g TOPICAL LOTION [Safe Sea SPF 30]
DrugBank: Octinoxate (DB09496)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Safe Sea (topical jellyfish sting inhibitor)
Trial: 11896407
Drug: RRV-TV (lower-titer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRV-TV (lower-titer formulation: 4 x 10(4) pfu/dose)
Trial: 1699861
Drug: Lymphoblastoid interferon
RxNorm normalized name: interferon alfa-n1 lymphoblastoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphoblastoid interferon therapy
Trial: 380609
Drug: Mepivacaine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepivacaine (250 mg i.v. infusion)
Trial: 380609
Drug: Prilocaine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prilocaine (250 mg i.v. infusion)
Trial: 6303793
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (CAMP-L: cyclophosphamide, doxorubicin, methotrexate, procarbazine, leucovorin)
Trial: 6303793
Drug: Sequential chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemotherapy (methotrexate/leucovorin followed by cyclophosphamide/doxorubicin at progression)
Trial: 29224638
Drug: Bridge therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bridge therapy with dalteparin 100 IU/kg twice daily
Trial: 29224638
Drug: Perioperative aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative aspirin use
Trial: 25432270
Drug: Practice-only condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Practice-only condition (weekly writing practice; n=39)
Trial: 16206354
Drug: Oral daily
RxNorm normalized name: Summer's Eve Sheer Floral Daily Cloths
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral daily ibandronate
Trial: 16206354
Drug: Intermittent ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent ibandronate (interval between doses > 2 mo)
Trial: 7011112
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg reproterol
Trial: 20011855
Drug: Epidural block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural block with 10 to 15 mL of 0.5% ropivacaine
Trial: 20011855
Drug: Lumbar plexus
RxNorm normalized name: Bos taurus solar plexus preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar plexus block with 0.4 mL.kg(‐1) of 0.5% ropivacaine
Trial: 17309918
Drug: HIF-1alpha (Ad2/HIF-1alpha/VP16)
RxNorm normalized name: 1alpha-hydroxycholecalciferol
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIF-1alpha (Ad2/HIF-1alpha/VP16) at doses of 1x10(8) to 2x10(11) viral particles
Trial: 11731907
Drug: Valeriana edulis
RxNorm normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valeriana edulis standardized hydroalcoholic extract (450 mg)
Trial: 11731907
Drug: Valeriana officinalis
RxNorm normalized name: VALERIANA OFFICINALIS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valeriana officinalis extract (450 mg)
Trial: 7512838
Drug: G-CSF (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (200 microgram/m2) starting daily from 2 days before induction therapy until neutrophils recovered to above 1,500/microL or until 35 days after therapy
Trial: 30889155
Drug: Fisionerv® gel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fisionerv® gel, 3 times/day added to physiotherapy (40 minutes daily session)
Trial: 30889155
Drug: Vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle gel (placebo, 3 times/day) added to physiotherapy (40 minutes daily session)
Trial: 30889155
Drug: Fisionerv® gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fisionerv® gel
Trial: 23297841
Drug: VEN‐XR (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VEN‐XR (up to 375 mg)
Trial: 21783417
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg/day) until disease progression or unacceptable toxic effects
Trial: 21783417
Drug: Chemotherapy (gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (gemcitabine plus carboplatin)
Trial: 17087700
Drug: Individual vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual vitamin or mineral supplement
Trial: 17087700
Drug: Nonvitamin/nonmineral dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonvitamin/nonmineral dietary supplement (NVNMDS)
Trial: 15234411
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose tolerance test in patients with IDCM
Trial: 19821105
Drug: rabdosia rubescens
RxNorm normalized name: Isodon rubescens top extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabdosia rubescens drop pill (960 mg) and 4 tablets of simulation agent, administered three times a day for 5 days
Trial: 19821105
Drug: rabdosia rubescens
RxNorm normalized name: Isodon rubescens top extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabdosia rubescens tablet (1000 mg) and 24 drop pills of simulation agent, administered three times a day for 5 days
Trial: 17760546
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel in a silica base for 2 minutes (G1)
Trial: 17760546
Drug: Neutral EDTA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral EDTA conditioning agent for 2 minutes followed by placebo gel (G2)
Trial: 17760546
Drug: 0.12% CHX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% CHX digluconate gel in a silica base (G3)
Trial: 17760546
Drug: Neutral EDTA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral EDTA conditioning agent for 2 minutes followed by CHX gel (G4)
Trial: 11172955
Drug: Post-treatment PCR
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment PCR results
Trial: 31151390
Drug: Arm 1
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm 1 (Usual Care): 10% cash back, no weekly text, standard monthly text
Trial: 31151390
Drug: Arm 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 2: 10% cash back, generic weekly text, standard monthly text